Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526341 | 0.89 | ALDH1A1 (0.34) | ALDH1A1GAAHRH3L3MBTL1POLB | |
| SCHEMBL996970 | 0.87 | MCHR1 (0.33) | ALDH1A1GAAHRH3L3MBTL1POLB | |
| SCHEMBL994826 | 0.83 | ALDH1A1 (0.35) | ALDH1A1POLBMMP1KDM4ECYP3A4 | |
| SCHEMBL2837627 | 0.82 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL3308918 | 0.82 | MCHR1 (0.35) | ALDH1A1HRH3L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL3314022 | 0.81 | ALDH1A1 (0.32) | ALDH1A1GAAHRH3KDM4EMAPK1 | |
| SCHEMBL995145 | 0.81 | MMP1 (0.34) | ALDH1A1GAAHRH3L3MBTL1MMP1 | |
| SCHEMBL2839916 | 0.79 | ALDH1A1 (0.33) | ALDH1A1KDM4ECYP3A4TSHRCYP2D6 | |
| SCHEMBL2837719 | 0.78 | KCNH2 (0.31) | — | |
| SCHEMBL995673 | 0.76 | CTSS (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| EP-2322516-B1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R & D IRELAND (IE) | 2015-08-06 | — | — | US | disclosed |
| US-9040562-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2015-05-26 | — | — | US | disclosed |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R&D IRELAND (IE) | 2014-09-11 | — | — | US | disclosed |
| US-8754106-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8349869-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2013-01-08 | — | — | US | disclosed |
| US-20120171157-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2012-07-05 | — | — | US | disclosed |
| US-8153800-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-12-01 | — | — | US | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1912999-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-05 | — | — | EP | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885GAA 4099/4885HRH3 403/4885 |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885GAA 4099/4885HRH3 403/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885GAA 4099/4885HRH3 403/4885 |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HCCS, CBR1, CYP2B6 | ALDH1A1 2716/4885GAA 4302/4885HRH3 160/4885 |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, HCCS, CYP3A7 | ALDH1A1 2770/4885GAA 4106/4885HRH3 431/4885 |
| US-20120171157-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885GAA 4099/4885HRH3 403/4885 |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | ALDH1A1 2683/4885GAA 4099/4885HRH3 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.